Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant.

Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant.

老虎证券老虎证券2026/02/17 13:18
Show original
According to the terms of the agreement, the generic drug applicant is prohibited from marketing generic versions of Nexletol® (bempedoic acid) and Nexlizet® (bempedoic acid/ezetimibe) before April 19, 2040. The conclusion of this agreement further consolidates the market exclusivity period for Esperion's core product portfolio. Nexletol and Nexlizet are important products for the company in the treatment of hypercholesterolemia, and the extension of their market exclusivity has a positive impact on the company's future revenue prospects.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share

Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

华尔街见闻•2026/11/21 12:01
Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share